MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

NCT06377540 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Autologous Stem Cell Transplant
Classic Hodgkin Lymphoma

Interventions

DRUG: Pembrolizumab
PROCEDURE: Autologous stem cell transplant
DRUG: Carmustine
DRUG: Etoposide
DRUG: Cytarabine
DRUG: Melphalan

Sponsor

Masonic Cancer Center, University of Minnesota